ClinicalTrials.gg
Not yet recruitingNCT07434167Updated Feb 25, 2026

Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

An interventional study of Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules in Lung Cancers, Metaverse and Extended Reality (XR), sponsored by National Taiwan University Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Lung Neoplasms by National Taiwan University Hospital — 12 open to participants now, 12 under way, 1 of them phase 3. Lung Neoplasms · National Taiwan University Hospital.

Planned enrollment
17th of 20
30 · median 103
Started
2026
with 3 others
No phase
16 of 46
3 open now
Primary completion
2026-12
later than 5 of 11 live
Registered
43rd of 46
by date

Among the 46 studies in Lung Neoplasms by National Taiwan University Hospital, this one is the 17th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 43rd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

12 of the 46 studies in Lung Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Lung Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

Read the detailed description

The objective of this study is to investigate the safety and feasibility of extended reality (XR)-assisted computed tomography (CT)-guided localization of pulmonary nodules for preoperative tumor localization. The study aims to utilize a fully developed XR system to assist physicians in performing preoperative localization of pulmonary tumors, while also optimizing the workflow and efficiency of pulmonary nodule localization in a conventional CT suite.

This study plans to enroll 30 patients at our institution who are scheduled to undergo thoracoscopic sublobar resection. The safety and feasibility of using an XR-assisted digital twin model for pulmonary nodule localization in a standard CT suite will be evaluated.

03

Conditions studied

  • Lung Cancers
  • Metaverse
  • Extended Reality (XR)

Browse trials for

Keywords

  • Metaverse
  • Extended Reality (XR)
  • Digital Twin
  • Localization of Pulmonary Nodules
  • uniportal VATS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery.
  • Patients with lung nodules smaller than 2 cm that require preoperative localization.
  • Patients with lung nodules located in the outer one-third of the lung.

Exclusion criteria

Exclusion Criteria:

  • Patients requiring lobectomy.
  • Patients who have not provided written .
  • Vulnerable populations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

    Procedure: Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

Interventions

  • ProcedureExtended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

    This study plans to collect approximately 30 localization cases from multiple centers within our institution. First, after patient positioning and immobilization in the computed tomography (CT) suite, a chest CT scan is performed. Imaging data are processed using semi-automatic segmentation and rapid reconstruction techniques to generate, in real time, a three-dimensional model that corresponds to the patient's current localization position. During the construction of the three-dimensional model, patients remain in a fixed position. To reduce anxiety and discomfort associated with waiting, patient education related to pulmonary nodule localization and thoracoscopic surgery is provided during this period. The educational content includes the purpose of the procedure, procedural steps, potential risks, and key points of postoperative care. Once model construction is completed, a metaverse-based XR platform is used in the same setting to overlay the digital twin model onto the patient's

06

What researchers measure

Primary outcomes

  1. Localization accuracy

    Procedures in this study will be conducted in a CT room. The accuracy of XR-assisted CT-guided localization will be assessed immediately after localization by employing in-room CT to determine the needle tip position and measure the distance to the target tumor.

    Time frame: Immediatedly after Extended Reality (XR)-Assisted CT-Guided Localization

Secondary outcomes

  1. Assessment of perioperative outcomes

    Perioperative outcomes, including intraoperative blood loss, localization time, operative time, and the rate of localization-related complications, will be measured. We will assess whether the incorporation of the localization system leads to reductions in these parameters.

    Time frame: The study assessment time frame from XR-assisted CT-guided localization to discharge is approximately 3 to 7 days.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data (IPD) collected during this study will generally not be shared with other researchers, primarily due to patient privacy considerations. However, limited access to de-identified IPD may be considered in exceptional cases upon a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 9 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 25, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07434167
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 25, 2026

Study contacts

Xu-Heng Chiang
Contact
lycansblueray@gmail.com
88672655136

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion